Immunogenicity and safety of an MF59-adjuvanted cell-derived higher-dose quadrivalent influenza vaccine (aQIVc) in adults aged 50 years or older: a phase 3 randomised controlled trial. (linkinghub.elsevier.com)

Authors: Essink BJ … Albano FR Journal: Lancet Infectious Diseases Published: 2026-09-10 DOI: https://doi.org/10.1016/S1473-3099(26)00410-X